Tissue Engineering Market Size, Share, Forecast, & Trends Analysis by Product (Scaffold [Collagen, PLA, Stem Cells], Tissue Grafts [Allograft, Xenografts, Autografts]) Application (Musculoskeletal, Oncology, Cardiology) End User – Global Forecast to 2031

The Tissue Engineering Market was valued at $1.91 billion in 2023. This market is expected to reach $7.41 billion by 2031 from an estimated $2.24 billion in 2024, at a CAGR of 18.6% during the forecast period of 2024-2031.

Tissue Engineering Market Size & Forecast

The growth of this market is driven by the rising approvals for tissue engineering products, rising demand for regenerative medicine, availability of funding for the development of tissue engineering products, and rising incidences of musculoskeletal disorders. Furthermore, advancements in tissue engineering products, the use of tissue engineering products in sports medicine, and the increasing application of tissue engineering products in newer therapy areas are expected to generate growth opportunities for the stakeholders in this market.

Key Findings

• By Product: The scaffold Segment Dominates the Tissue Engineering Market in 2024
• By Application: The Musculoskeletal & Orthopedics Segment to Dominate the Tissue Engineering Market in 2024
• By End User: The Hospitals & Clinics Segment is Expected to Dominate the Tissue Engineering Market in 2024
• By Geography: North America to Dominate the Tissue Engineering Market in 2024

Tissue Engineering Market Driver

Rising Approvals for Tissue Engineering Products

Tissue engineering leverages the body's natural healing mechanisms to repair, restore, or regenerate damaged or diseased tissues. The field has gained significant momentum in recent years, fueled by its promising applications across oncology, cardiology, neurology, and other medical specialties. Regulatory agencies, such as the FDA and EMA, are increasingly acknowledging the potential of regenerative therapies, including tissue engineering, to address critical unmet medical needs. This recognition is facilitating the market entry of innovative treatments, offering patients advanced solutions for a range of conditions. With the implementation of streamlined regulatory pathways, such as accelerated approval processes and orphan drug designations, approval timelines for tissue engineering products have been notably shortened, encouraging further research and investment in the field. As tissue engineering's applications expand across various therapeutic areas, regulatory bodies are progressively granting approvals for these products. Some of the recent approvals for tissue engineering products include:

• In May 2024, Medtronic plc (Ireland) received FDA Breakthrough Device Designation for its Infuse bone graft with intervertebral fusion device. This expands its product portfolio in the cranial and spinal technologies segment.

• In April 2024, Abbott Laboratories (U.S.) received regulatory approval for the verolimus-eluting bioresorbable scaffold (Esprit BTK) for the treatment of patients with below-the-knee (BTK) infrapopliteal disease.
• In June 2023, the Indian Drugs Controller approved an animal-derived tissue engineering scaffold for healing skin wounds with minimum scarring. The tissue engineering scaffold is made up of mammalian organs called Cholederm.

Tissue Engineering Market Trends

Use of 3D Bioprinting

In regenerative medicine, 3D bioprinting represents an innovative approach to creating functional, three-dimensional tissues using living cells and biomaterials, as opposed to traditional materials like metals and polymers. This technology's ability to produce highly specialized tissue models has gained significant attention in recent years, driving its growing application in tissue engineering. 3D bioprinting enables the precise assembly of living cells, biochemicals, and biomaterials into complex structures that mimic the function of natural tissues. This capability facilitates the integration of engineered tissue with native tissue, promoting the restoration of organ and tissue function. As a result of its advantages, 3D bioprinting is gradually replacing conventional methods. Compared to traditional techniques, 3D bioprinting ensures the accurate construction of scaffolds and optimal cell line interactions. Furthermore, it allows for the creation of tissue components derived from a patient's stem cells, which reduces the risk of immune rejection and graft-versus-host disease, driving increased adoption of this transformative technology.

Use of AI in Tissue Engineering

Traditional tissue engineering methods face several challenges, including the management of large volumes of data, increasing data complexity, and the potential for human error. To overcome these obstacles, there is a growing trend toward leveraging artificial intelligence (AI) for data analysis, enabling the identification of patterns and correlations to support treatment development. AI algorithms are becoming indispensable in tissue engineering, as they can detect patterns in cell interactions and behavior, allowing for the prediction of cell responses across various environments. This data-driven approach is instrumental in the development of functional tissues and organs.

Moreover, AI is being explored for its potential in biomanufacturing within regenerative medicine. For example, in April 2024, researchers at Northeastern University (U.S.) introduced a framework for integrating AI into the large-scale production of pluripotent stem cells. These engineered stem cells hold significant promise for treating a range of diseases, including Alzheimer's and Parkinson's, combating cancer, repairing spinal cord injuries, and addressing age-related conditions.

Tissue Engineering Market Opportunities

Utilization of Tissue Engineering Products in Sports Medicine

Tissue engineering is increasingly utilized in sports medicine when traditional nonsurgical treatments fail to heal sports-related injuries. It is primarily applied to repair or replace damaged ligaments, cartilage, or tendons. In this context, tissue engineering plays a crucial role in restoring, protecting, or healing injured tissues or improving the function of organs that have suffered damage or defects. Soft tissue allografts, which serve as critical substitutes, are commonly used for reconstructing damaged ligaments, torn menisci, and osteochondral defects, offering a viable solution for addressing these complex injuries.

Professional athletes are increasingly turning to tissue engineering for treatment, as these therapies offer significantly shorter recovery times compared to traditional methods. Additionally, tissue engineering presents a low risk of adverse effects, involves minimally invasive procedures, eliminates the need for prolonged post-surgery recovery, and provides permanent restoration of damaged tissue structures. This growing preference is being driven by the rising number of individuals participating in sports, presenting a substantial growth opportunity for the market. For example, in Ireland, sports participation increased by 3% between 2021 and 2022 (Source: Irish Sports Monitor). Similarly, according to the Sports and Fitness Industry Association, in 2023, 242 million people, or 78.8% of the North American population, engaged in at least one physical activity, marking a 2.2% increase from the previous year.

Tissue Engineering Market Analysis: Top Market Opportunity:

The Musculoskeletal & Orthopedics Segment is Expected to Dominate the Tissue Engineering Market in 2024

Based on application, the tissue engineering market is segmented into musculoskeletal & orthopedics, oncology, immunology and inflammation, neurology, dermatology, cardiology, and other applications. In 2024, the musculoskeletal & orthopedics segment is estimated to account for the largest share of the tissue engineering market. The largest share of the segment can be attributed to the rising prevalence of musculoskeletal disorders, the growing demand for bone tissue engineering, and the increasing incidence of road accidents. In the event of road accidents, tissue engineering products play a critical role in reconstructing and repairing damaged tissues.

Additionally, orthopedic surgeons are increasingly using tissue engineering as a therapeutic option for treating a variety of musculoskeletal lesions, from meniscal deficiencies in young athletes to osteochondral defects in the glenohumeral joint. The rising incidence of sports-related injuries is further driving the demand for tissue engineering products. According to the Centers for Disease Control and Prevention (CDC), more than 3.5 million sports injuries occur annually in the U.S., highlighting the growing need for advanced treatment solutions in this area.

Geographical Analysis

North America Dominates the Tissue Engineering Market in 2024

In 2024, North America is estimated to account for the largest share of the tissue engineering market. The dominant share of this regional market is driven by several factors, including the rising prevalence of chronic conditions such as cancer, neurological disorders, and cardiovascular diseases, as well as increased funding for tissue engineering development. The presence of leading tissue engineering manufacturers in the region, growing awareness of the benefits of tissue engineering, and the active involvement of academic and research institutions in advanced R&D also contribute to market growth. Additionally, strong support from government bodies and regulatory authorities is promoting the adoption of tissue engineering products for medical applications. Both public and private organizations in the region are providing critical funding to advance tissue engineering innovation. For example, in July 2024, the Canadian government allocated USD 22.5 million to STEMCELL Technologies for the development of a state-of-the-art facility in Burnaby, British Columbia. This facility is designed to support the manufacturing and clinical trials of cell therapy, gene therapy, tissue engineering, and immunotherapy to address various chronic and degenerative conditions.

However, Asia-Pacific is slated to register the highest CAGR during the forecast period. Asia-Pacific is emerging as one of the fastest-growing markets for tissue engineering, fueled by increasing healthcare expenditures, a rapidly aging population, and a rising incidence of target diseases. Furthermore, the region is witnessing a surge in conferences dedicated to advancing tissue engineering and robust research initiatives, which are expected to significantly enhance awareness and drive broader adoption of these therapies.

Key Companies

The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past three years. Some of the key players operating in global tissue engineering market report are Smith & Nephew plc (U.K.), Integra LifeSciences Holdings Corporation (U.S.), AbbVie Inc. (U.S.), Medtronic plc (Ireland), Zimmer Biomet Holdings, Inc. (U.S.), Organogenesis Inc. (U.S.), Becton, Dickinson and Company (C. R. Bard) (U.S.), Baxter International Inc. (U.S.), Octane Medical Group (Canada), Tissue Regenix Group plc (U.K.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.).

Tissue Engineering Industry Overview: Latest Developments from Key Industry Players

• In March 2024, HVD Life Science Vertriebs-GmbH (Austria) partnered with Poietis (France) for the distribution of the NGB-RTM Bioprinting platform in Austria and Germany. This collaboration brings cutting-edge bioprinting technology to the forefront of R&D in tissue engineering and regenerative medicine.
• In October 2023, Smith & Nephew plc (U.K.) launched the REGENETEN Bioinductive Implant in Japan. This wound care patch supports new tendon-like tissue growth and initiates biological tendon regeneration.
• In May 2022, Darling International Inc. (U.S.) health brand Rousselot launched a Quali-Pure HGP 2000, a new pharmaceutical-grade, endotoxin-controlled gelatin specifically designed for vaccines and wound healing applications.
• In February 2022, Orthofix Medical Inc. (U.S.) launched an Opus BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures.

Tissue Engineering Market Research Summary

Key questions answered in the tissue engineering market report: